Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06643754 | A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 115 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06739395 | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | recruiting | Phase 2 | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05315167 | A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 267 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06112704 | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | recruiting | Phase 2 | 220 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06117566 | A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Jiatan Pharmatech Co., LtdINDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06117540 | A Study of WX390 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 70 | Shanghai Jiatan Pharmatech Co., LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06003621 | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients(MoST-TAP) | recruiting | Phase 2 | 96 | OmicoOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT05367778 | Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 176 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | recruiting | Phase 1 / Phase 2 | 144 | Eisbach Bio GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06551051 | ADC-induced Neurotoxicity Treated With Duloxetine | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06185556 | COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases(COLDFIRE-III) | recruiting | Phase 2 / Phase 3 | 78 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06081907 | The Efficacy and Safety of IBI363 in Solid Tumors(Promise) | recruiting | Phase 1 / Phase 2 | 430 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03767075 | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)(BoB) | recruiting | Phase 2 | 1,000 | Vall d'Hebron Institute of OncologyOTHER | 7 | Apr 25, 2024 | clinicaltrials |
| NCT06314373 | A Study for HSK39775 in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 243 | Xizang Haisco Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04165590 | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05923008 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 182 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05947487 | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05909436 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | recruiting | Phase 1 / Phase 2 | 107 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 8, 2025source: clinicaltrials